Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The practical comparison: Neither form is universally superior
Retatrutide Sexual Function Impact: What the Phase 2 Data Actually Show At a glance Drug / retatrutide (LY3437943), investigational triple GIP/GLP-1/glucagon receptor agonist Phase 2 trial / Jastreboff et al., NEJM 2023, N=338 adults with obesity Peak weight loss / 24.2% mean body-weight reduction at 48 weeks (12 mg dose) Sexual-function endpoints / not prespecified in Phase 2
Understanding the Math: Concentration = Total Peptide (mg) Diluent Volume (mL) Volume per Dose = Desired Dose (mg) Concentration (mg/mL) Units = Volume (mL) 100 (for U-100 scale) Note: These are theoretical calculations for educational purposes
Discovery of a novel glucagon-like peptide-1 (GLP-1) analogue from bullfrog and investigation of its potential for designing GLP-1-based multiagonists
That's a 111% increase in just one year
US$ 22.89
US$ 22.90
US$ 22.65
US$ 20.48
US$ 22.73
US$ 23.84
